Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19
- 14 May 2022
- journal article
- Published by Mediar Press in Rheumatology Science and Practice
Abstract
Immune-mediated rheumatic diseases (IMRDs), based on the leading mechanisms of pathogenesis, are conditionally classified into autoimmune, autoinflammatory, and «mixed pattern». In the spectrum of cytokines involved in the development of the immunopathological process in IMRDs, the “pro-inflammatory” cytokine interleukin (IL) 18, a member of the IL-1 family, plays an important role in the regulation of T-helper (Th) 1-, Th2- and Th17- types of immune response that induces the synthesis of interferon (IFN) γ, other pro-inflammatory cytokines and chemokines. The possibility of determining the concentration of IL-18 in IMRDs is discussed to improve diagnosis, identify subtypes of diseases, and predict the effectiveness of pharmacotherapy. IL-18 is a promising target for anticytokine therapy, primarily in patients with high activity of inflammation associated with hyperactivation of innate immunity.Keywords
This publication has 100 references indexed in Scilit:
- Stronger Correlation between Interleukin 18 and Soluble Fas in Lupus Nephritis Compared with Mild LupusISRN Rheumatology, 2013
- Protection from Inflammatory Organ Damage in a Murine Model of Hemophagocytic Lymphohistiocytosis Using Treatment with IL-18 Binding ProteinFrontiers in Immunology, 2012
- Inflammation in the Central Nervous System and Th17 Responses Are Inhibited by IFN-γ–Induced IL-18 Binding ProteinThe Journal of Immunology, 2010
- Expressions of IL-18 and its binding protein in peripheral blood leukocytes and kidney tissues of lupus nephritis patientsClinical Rheumatology, 2010
- IL‐18 Activity in Systemic Lupus ErythematosusAnnals of the New York Academy of Sciences, 2009
- Increased Spontaneous But Decreased Mitogen-stimulated Expression and Excretion of Interleukin 18 by Mononuclear Cells in Patients with Active Systemic Lupus ErythematosusThe Journal of Rheumatology, 2009
- A Proposed Classification of the Immunological DiseasesPLoS Medicine, 2006
- Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosusRheumatology, 2006
- Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosusClinical Rheumatology, 2004
- Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosusLupus, 2002